Olaparib treatment in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Phase II LIGHT study.

Karen Anne Cadoo,Fiona Simpkins,Cara Mathews,Nashwa Kabil,James Bennett,Carol Aghajanian

Olaparib treatment in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Phase II LIGHT study.

2020

Karen Anne Cadoo
Fiona Simpkins
Cara Mathews
Nashwa Kabil
James Bennett
Carol Aghajanian

6013Background: In Study 19 (NCT00753545), olaparib capsules demonstrated improvement in progression-free survival (PFS) vs placebo in the PSR OC maintenance setting, irrespective of BRCAm status (...

Keywords:

Homologous Recombination Deficiency
Olaparib
in patient
Ovarian cancer
BRCA mutation
Pathology
platinum sensitive
Medicine
Cancer research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations